Yunnan Baiyao Group

Yunnan Baiyao Group is a pharmaceuticals company spanning pharmaceuticals, personal healthcare, Chinese medical resources, and medicine logistics.

: Public company
: 1971
: Kunming, Yunnan, CNChina

Library

yunnanbaiyao.com.cnCrawled Oct 26, 2026

Product

6 pages

Chinese Medicine/list/ynbyEn/3/130/auto/20/0.html
Drugs/list/ynbyEn/3/128/auto/20/0.html
Medical devices/list/ynbyEn/3/129/auto/20/0.html
Medicine business/list/ynbyEn/3/132/auto/20/0.html

Press

1 page

Yunnan Baiyao Group Co., Ltd. Interim Report 2023/view/ynbyEn/3/397/view/6780.html
Yunnan Baiyao Group Co., Ltd. reports its 2023 interim results, highlighting over a century of history and its widely sold products.

About

6 pages

About/list/ynbyEn/3/117/auto/20/0.html
Our Awards and Recognition/list/ynbyEn/3/119/auto/20/0.html
Our History/list/ynbyEn/3/118/auto/20/0.html
Our structure/list/ynbyEn/3/291/auto/20/0.html

Contact

1 page

Contact/list/ynbyEn/3/115/auto/20/0.html

Homepage

1 page

Homepage/
Yunnan Baiyao has over 100 years of history and remains a best-selling brand both domestically and internationally, with its formula protected as a state economic trade secret.

Coverage

5 items

Yunnan Baiyao Group Co.,Ltd Approves Special Dividend for the Year 2026 on A Shares, Payable on 24 September 2026marketscreener.com/news/yunnan-baiyao-group-co-ltd-approves-special-dividend-for-the-year-2026-ce785bd2d180fe24
Yunnan Baiyao Group Co.,Ltd approves a special dividend for 2026, payable to A Shares holders on **24 September 2026**. The decision follows the company’s **1st Extraordinary General Meeting of 2026**, held on **15 September 2026**. The dividend distribution plan was formally adopted during the meeting.
Sep 2026MarketScreenerNews article
TCM firm enters innovative pharmachinadaily.com.cn/a/202604/22/WS69e836dda310d6866eb44d86.html
Yunnan Baiyao Group, a century-old traditional Chinese medicine (TCM) brand, expands into innovative pharmaceuticals while maintaining its focus on TCM. The company leverages its heritage to develop modern drug formulations, bridging traditional and contemporary medical approaches.
Apr 2026chinadaily.com.cnNews article
Norway wealth fund to divest from Chinese pharma firm over pangolinsthestandard.com.hk/china/article/184944/Norway-wealth-fund-to-divest-from-Chinese-pharma-firm-over-pangolins
Norway’s **$1.4 trillion sovereign wealth fund** divests from **Yunnan Baiyao**, a Chinese pharmaceutical company, due to its use and sale of pangolin body parts, an endangered species. The fund also places **Marfrig Global Foods**, Brazil’s largest beef producer, under review for potential exclusion over environmental harm. The decision reflects the fund’s stance on sustainability and ethical investing.
Dec 2021thestandard.com.hkNews article
Norway’s Sovereign Wealth Fund excludes Chinese medicine stocks on species concernsscandasia.com/norways-sovereign-wealth-fund-excludes-chinese-medicine-stocks-on-species-concerns/
Norway’s Government Pension Fund Global excludes Chinese companies involved in traditional medicine due to animal welfare and species conservation risks. The fund, one of the world’s largest, removes stocks linked to practices like bear bile extraction and tiger bone use. This decision follows ethical investment guidelines prioritizing sustainability and biodiversity protection.
Oct 2021ScandasiaNews article